Effect of Amphotericin B on Treatment of Chronic Rhinosinusitis: A Double-blind Randomized Clinical Trial

• Main Authors: Jaleh Yousefi, Asghar Akhavan, Reza Hoseini-Motlagh, Shahin Banaei-Boroujeni, Yunes Panahi, Mohammad Hossein Khosravi
• Format: Article
• Language: English
• Published: Razavi Hospital, Mashhad, Iran 2017-12-01
• Series: Razavi International Journal of Medicine
• Online Access: http://dx.doi.org/10.5812/rijm.64550
• ISSN: 2345-6426; 2345-6434

Background Chronic rhinosinusitis (CRS) is the inflammation of paranasal sinus mucous membranes. Considering the influence of fungi on chronic rhinosinusitis and different results concerning the effect of Amphotericin B on improvement of this condition; this study aimed to determine the effect of topical Amphotericin B on improvement of the symptoms in patients with CRS. Methods In this double-blind randomized clinical trial, 80 patients with chronic rhinosinusitis who visited the allergy clinic of Baqiyatallah Hospital from June to October 2014 were randomly allocated to two groups; the first group received 10 cc topical lavage of Amphotericin B (5 cc each nostril for every 12 hours) and the second group received placebo for three months. Symptoms, nasal mucusa smear, serum level of inflammatory cytokines, CT scan and rhinoscopy score changes were evaluated in both groups after three months. Results Fifty-five male and 25 female patients were evaluated in two groups. The mean age was 26.1 ± 2.36 and 27.9 ± 1.59 years in intervention and control groups respectively (P = 0.08). There were no significant differences in demographic data between the groups (P > 0.05). Nasal obstruction, post nasal drip (PND), reduced sense of smell, quality of life, CT scan and rhinoscopy scores were not significantly different between the two groups after intervention (P > 0.05). Facial pain severity score was significantly more reduced in intervention group in comparison with control group (P < 0.01). Conclusions We concluded that application of Amphotericin B as an adjunctive medication to other common treatments, does not seem to be an efficient method for improvement of CRS symptoms.